Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma

<div>The process for MM response prediction of bortezomib, cyclophosphamide, and dexamethasone (BCD) and bortezomib, lenalidomide, and dexamethasone (VRD).</div>

BioMed Research International

fig2

Figure 2

Figure 2: Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma 

Figure 2 | Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma 